SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-123568
Filing Date
2022-04-27
Accepted
2022-04-27 16:02:03
Documents
5
Period of Report
2022-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A d286815ddef14a.htm DEF 14A 448296
2 GRAPHIC g286815g04p28.jpg GRAPHIC 173711
3 GRAPHIC g286815g05p37.jpg GRAPHIC 97606
4 GRAPHIC g286815g10n62.jpg GRAPHIC 46237
5 GRAPHIC g286815g14a35.jpg GRAPHIC 28499
  Complete submission text file 0001193125-22-123568.txt   915465
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39397 | Film No.: 22859440
SIC: 2834 Pharmaceutical Preparations